Wilmington, DE, United States of America

Taisheng Huang

This inventor holds 21 USPTO granted patents and 11 published patent applications, plus 3 CIPO patents and 8 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Incyte Corporation, Incyte Holdings Corporation, Incyte Holdings Cororation. Active years: 2010-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Taisheng Huang. Retrieved from https://idiyas.com/inventor/taisheng-huang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21 (Patent Applications = 11)

% Patents Active = 95.2

CIPO Patents = 3 (Patent Applications = 6)

EPO Patents = 8 (Patent Applications = 15)

Average Co-Inventor Count = 4.4

ph-index = 8

Forward Citations = 300(Granted Patents)

Company Filing History:

Incyte Holdings Corporation

patents

1 out of 1

Incyte Holdings Cororation

patent

where one patent can have more than one assignee

Years Active: 2010-2025

Loading Chart...

Areas of Expertise:

Adenosine Receptor Inhibitors

JAK1 Inhibitors

KRAS Inhibitors

Pyrrolotriazine Compounds

Pyrazolopyridines

Bicyclic Dione Compounds

Piperidin Derivatives

Isoindolinone Derivatives

Chemokine Receptor Antagonists

Furo-Pyridine Compounds

Thieno-Pyridine Compounds

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12415809 - Pyrrolotriazine compounds as tam inhibitors (2025-09-16),

2. 12060433 - CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapy (2024-08-13),

3. 11884665 - Pyrazolopyridines and triazolopyridines as A2A / A2B inhibitors (2024-01-30),

4. 11767320 - Bicyclic dione compounds as inhibitors of KRAS (2023-09-26),

5. 11673894 - Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors (2023-06-13),

6. 11390624 - Pyrazolopyridines and triazolopyridines as A2A / A2B inhibitors (2022-07-19),

7. 11285140 - Piperidin-4-yl azetidine derivatives as JAK1 inhibitors (2022-03-29),

8. 11220510 - Pyrrole tricyclic compounds as A2A / A2B inhibitors (2022-01-11),

9. 10695337 - Piperidin-4-yl azetidine derivatives as JAK1 inhibitors (2020-06-30),

10. 10053465 - Pyrrolopyrimidine derivatives as TAM inhibitors (2018-08-21),

11. 9999619 - Piperidin-4-yl azetidine derivatives as JAK1 inhibitors (2018-06-19),

12. 10000507 - Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors (2018-06-19),

13. 9556197 - Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors (2017-01-31),

14. 9464088 - Piperidin-4-yl azetidine derivatives as JAK1 inhibitors (2016-10-11),

15. 9067921 - Piperazinylpiperidine derivatives as chemokine receptor antagonists (2015-06-30),

Title: Taisheng Huang: Pioneering Advances in Adenosine Receptor Inhibition

Introduction

Taisheng Huang is a distinguished inventor based in Wilmington, DE, who has made significant contributions to the field of medicinal chemistry, particularly in the development of innovative therapies targeting adenosine receptors. With a remarkable portfolio of 20 patents, Huang is at the forefront of research aimed at combatting various diseases, including cancer and inflammatory conditions.

Latest Patents

Among Taisheng Huang's notable patents are his groundbreaking inventions related to combination therapies that include a CD73 inhibitor and A2A/A2B adenosine receptor inhibitor. These combination therapies are designed to address diseases associated with the activity of adenosine receptors and CD73, such as cancer, inflammatory diseases, cardiovascular issues, and neurodegenerative disorders. His recent applications also feature the creation of novel pyrazolopyridines and triazolopyridines that function as A2A/A2B inhibitors, presenting promising opportunities for the treatment of diseases linked to adenosine receptor activities.

Career Highlights

Taisheng Huang’s career includes significant roles at renowned organizations such as Incyte Corporation and Incyte Holdings Corporation. His work at these institutions has not only contributed to the advancement of pharmaceutical innovations but has also solidified his reputation as a leader in the field of adenosine-based therapies.

Collaborations

Throughout his career, Huang has collaborated with esteemed professionals, including notable colleagues like Chu-Biao Xue and Anlai Wang. These partnerships have enhanced his research efforts and facilitated the development of impactful therapeutic solutions.

Conclusion

Taisheng Huang’s innovative work in the realm of adenosine receptor inhibitors marks a substantial contribution to medical science. His extensive patent portfolio and collaborations highlight his dedication to improving treatment options for complex diseases. As research progresses, Huang's inventions will likely play a pivotal role in advancing healthcare and patient outcomes.

Profile summary based on public USPTO records.